Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market

Author:

Shabaninejad Hosein,Mehralian Gholamhossein,Rashidian Arash,Baratimarnani Ahmad,Rasekh Hamid Reza

Abstract

Abstract Background Pharmaceutical industry is knowledge-intensive and highly globalized, in both developed and developing countries. On the other hand, if companies want to survive, they should be able to compete well in both domestic and international markets. The main purpose of this paper is therefore to develop and prioritize key factors affecting companies’ competitiveness in pharmaceutical industry. Based on an extensive literature review, a valid and reliable questionnaire was designed, which was later filled up by participants from the industry. To prioritize the key factors, we used the Technique for Order Preference by Similarity to Ideal Solution (TOPSIS). Results The results revealed that human capital and macro-level policies were two key factors placed at the highest rank in respect of their effects on the competitiveness considering the industry-level in pharmaceutical area. Conclusion This study provides fundamental evidence for policymakers and managers in pharma context to enable them formulating better polices to be proactively competitive and responsive to the markets’ needs.

Publisher

Springer Science and Business Media LLC

Subject

Applied Mathematics,General Mathematics

Reference59 articles.

1. Munos B: Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009, 8: 959-968. 10.1038/nrd2961.

2. Hsieh PH, Mishra CS, Gobeli DH: The return on R&D versus capital expenditures in pharmaceutical and chemical industries. IEEE Trans Eng Manag. 2003, 50: 141-150. 10.1109/TEM.2003.810828.

3. Rasekh HR, Mehralian GH, Vatankhah-Mohammadabadi AA: Situation analysis of R&D activities: an empirical study in iranian pharmaceutical companies. Iran J Pharm Res. 2012, 11: 1013-1025.

4. Engelhardt HT, Garrett JR: Innovation And The Pharmaceutical Industry: Critical Reflections On The Virtues Of Profit. 2008, United States: M & M Scrivener Press

5. Schweizer L: Organizational integration of acquired biotechnology companies into pharmaceutical companies: the need for a hybrid approach. Acad Manage J. 2005, 48: 1051-1074. 10.5465/AMJ.2005.19573109.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3